CNPS is at the forefront of next-generation energy materials, specializing in advanced binder materials for LIBs. With a strong commitment to environmental sustainability and regulatory compliance, CNPS pioneers the development of fluorine-free binder systems—an increasingly critical need as the industry moves away from PFAS-based compounds like PVDF and PTFE. Our core expertise lies in designing binders specifically engineered for dry electrode technology, enabling better electrode characteristics and electrochemical cell performance. In parallel, we work closely with the development of multi-roll dry electrode equipment for continuous process from powder feeding to electrode calendering. CNPS is helping shape the future of LIBs, empowering OEMs and cell manufacturers to meet the rising demand for greener, more cost-effective energy and scalable energy storage solutions. We are proud to lead the shift toward a fluorine-free battery ecosystem.
CNCure Co., Ltd.
CNCure is a pioneering biotech startup dedicated to revolutionizing cancer therapy and diagnostics. We specialize in developing bacteria-based cancer immunotherapeutics and theranostic platforms leveraging microbial theapeutics and nuclear medicine. One of our core technologies is the Salmonella-based Armed Microbe (SAM) platform, which utilizes innovative approaches to target tumors and enhance anticancer immune responses. Our flagship products, CNC-101 and CNC-105, directly target tumors, induce immune responses, and establish long-term antitumor immunological memory to prevent recurrence. In addition, CNCure is advancing diagnostic technologies with radiotracer-based tools for the high-sensitivity detection of fatal diseases such as fungal infections. Our [18F]FDS and [18F]DMPY2 tracers enable high-resolution visualization of gram-negative bacterial and fungal infections and malignant melanoma, respectively. CNCure is dedicated to pioneering innovations in cancer treatment, striving to improve patient outcomes and quality of life on a global scale. By actively participating in numerous national and international R&D projects, we continue to drive groundbreaking research and development. Our extensive patent portfolio is a testament to our technological excellence and commitment to shaping the future of oncology. Founded in 2019 by leading experts in cancer immunotherapy and radiopharmaceuticals, CNCure has developed a robust scientific foundation, a cutting-edge technology platform, and a strong pipeline. In the second half of 2024, we were honored to be one of only 14 companies, out of over 100 applicants, selected for Johnson & Johnson’s JLABS Korea program, which aims to accelerate life-science innovation. As we advance the clinical development and commercialization of our theranostic candidates, we actively seek joint-development partnerships and investments to expand our global presence. Our vision is to revolutionize cancer treatment through groundbreaking bacteria-based immunotherapies and radiopharmaceuticals that address critical unmet medical needs. | CNCure Co., Ltd. is a pioneering biotechnology company based in Hwasun, Republic of Korea, dedicated to revolutionizing cancer therapy and diagnostics. Founded in 2019, CNCure specializes in bacteria‑based cancer immunotherapeutics and integrated theranostic platforms leveraging microbial and nuclear medicine. The company’s lead candidate, CNC‑101, is a next‑generation bacterial immunotherapy built on attenuated Salmonella typhimurium technology, designed to selectively colonize the tumor microenvironment and reprogram it into an immuno‑active state that enhances anti‑tumor immune responses. Preclinical data demonstrate promising efficacy and safety profiles across multiple solid tumor models. Beyond immuno‑oncology, CNCure is advancing radiopharmaceutical and theranostic platforms that combine imaging and therapy for improved tumor targeting, treatment monitoring, and personalized decision‑making. CNCure actively pursues global partnerships and business development to translate its innovative platforms into clinical applications that address unmet medical needs. CNCure continues to present its scientific and clinical progress at major international conferences.
CMV Hoven GmbH
CMV has more than 40 years of experience in sales, consulting and engineering. The implementation of various application requirements and individual complete solutions for our customers from different areas of industry, automotive, aerospace, authorities and institutions with safety-relevant tasks are among our main tasks. We offer sensors and systems that are used across a wide range of applications within test and measurement, medical, dental, and retail; as stand-alone solutions or as embedded technology to create better and differentiated products.
CME Technology Co., Ltd.
CME Technology Co., Ltd. is specializing in manufacturing equipment for mechanical testing and simulation, environmental reliability testing.Products including1. Shock Test Systems – Specifically engineered for battery shock testing.2. SRS Test Equipment – State-of-the-art equipment for conducting SRS (Shock Response Spectrum) tests.3. Hydraulic Vibration Shakers – Especially for high force and low frequency vibration testing.4. Constant Acceleration Testers – Adopt in aerospace and aviation industry.5. Multi-DOF Motion Simulation Tables – Cutting-edge tables that enable multi-degree-of-freedom motion simulation for comprehensive testing.6. Packaging Test Machines – We are ISTA and EUMOS membership, our products are dedicated to meet ISTA standards.
Clover
There’s a Clover for Every Restaurant Clover is the world’s smartest all-in-one POS system, combining hardware & software to power small to medium-sized businesses across the world, with a keen focus in restaurants. https://clover.com | Clover is a safety-tech brand dedicated to preventing and detecting drink spiking through three complementary solutions: a reusable detection device connected to a mobile app, and a physical drink protection. Its goal is to secure drink consumption, protect guests and venues, and restore freedom and confidence in nightlife environments. | Fiserv, a global leader in financial services technology, and Clover, our powerhouse point-of-sale (POS) platform, are here to revolutionize the way you manage payments and operations. Our partnership with IAAPA means that you gain access to premier benefits designed to elevate your business. | Power your business with a complete point-of-sale system that’s easy to work with and customize. With Clover, you can do it all, from payments to operations and business management.
Cliniphai
Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences. The company’s flagship platform, Athena, is an AI-powered clinical translation and localization workbench focused on delivering secure, compliant, and high-quality solutions for life sciences, healthcare, and pharmaceutical organizations. Founded by industry veterans in clinical trial execution, technology development, and regulatory compliance, Cliniphai is redefining how organizations approach AI in life sciences without compromising accuracy, security, or compliance. For more information, visit www.cliniphai.com.
Clinia
Clinia helps health organizations and digital health builders make sense of and act on fragmented health data. Our platform offers embeddable search, summarization, and conversational UI components that integrate directly into EHRs, patient portals, and existing workflows, as well as flexible APIs that enable technical teams to build fully customized retrieval, question-answering, and AI-powered conversational experiences. By grounding every interaction in governed health data, Clinia delivers the precise context clinicians, patients, and AI agents need to act with clarity and confidence.
CLICK GENERATION S.R.L. S.B.
Limbico is a wearable + AI platform that turns stress and fatigue from invisible risks into measurable KPIs. Real-time insights on stress, focus and overload power a mental performance dashboard with actionable recommendations, boosting performance while protecting teams from burnout.
Click Therapeutics
Click Therapeutics is the leader in prescription digital therapeutics. Our assets are entirely digital and our software is the medicine. Unique amongst our peers, we are a biotechnology platform company with end-to-end development capabilities that enable a rigorous approach to the design and validation of our digital therapies. To date, we have announced four industry-leading co-development and commercialization collaborations with pharmaceutical companies and have five prescription treatments under active development. In collaboration with Otsuka, we developed RejoynTM, the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms. Two additional treatments have received breakthrough designation from the FDA. Our evidence-based mobile applications safely target neural pathways often inaccessible to biopharmaceuticals; their consistent use is designed to modify the underlying neurological basis of disease to achieve lasting improvement across well-established measures of function, behavior, cognition, disease severity, and disease progression. In short, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. As the only innovator of prescription digital therapeutics to take a biotech-like approach to development, we are committed to applying the technical and scientific rigor that is necessary to meet the needs of payers, providers, and patients. We clinically validate our applications through randomized controlled trials to demonstrate safety and efficacy. We seek FDA clearance for our treatments as class II medical devices with independent or adjunctive therapeutic treatment claims or FDA approval as drug-device combinations. Our end-to-end capabilities and clinically validated platform enable us to develop products in-house and in collaboration with pharma partners. As a result, we are uniquely positioned to support the digitization of pharma pipelines via prescription drug use-related software (PDURS) combinations that can expand drug labels with additional efficacy claims. Our digital therapeutics under development address diverse areas of unmet need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral, and neuromodulatory mechanisms of action and advanced data-driven tools, such as artificial intelligence and machine learning, to create uniquely engaging experiences for patients seeking new treatment options.